{"id":5621,"date":"2022-12-06T14:01:28","date_gmt":"2022-12-06T13:01:28","guid":{"rendered":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/stayble-therapeutics-presenterar-den-pagaende-fas-2b-studien-vid-european-congress-on-clinical-trials-in-pain\/"},"modified":"2022-12-06T14:01:28","modified_gmt":"2022-12-06T13:01:28","slug":"stayble-therapeutics-presenterar-den-pagaende-fas-2b-studien-vid-european-congress-on-clinical-trials-in-pain","status":"publish","type":"cision-feed","link":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/stayble-therapeutics-presenterar-den-pagaende-fas-2b-studien-vid-european-congress-on-clinical-trials-in-pain\/","title":{"rendered":"Stayble Therapeutics presenterar den p\u00e5g\u00e5ende fas 2b-studien vid European Congress on Clinical Trials in Pain"},"content":{"rendered":"

Stayble meddelar att Bolaget kommer presentera den p\u00e5g\u00e5ende fas 2b-studien med STA363 vid European Congress on Clinical Trials in Pain i Wien. Abstraktet har titeln <\/span>Safety and Tolerability of STA363 in Patients with Degenerative Disc Disease<\/em><\/span> och kommer presenteras av Anders Lehmann, Chief Scientific Officer (CSO) i Stayble. <\/span><\/p>\n

 <\/span><\/p>\n

SOPATE2022 \u00e4r en ansedd konferens som \u00e4ger rum 7-8 december 2022 i Wien, \u00d6sterrike. Kongressen \u00e4r inriktad mot kliniska pr\u00f6vningar i sm\u00e4rta och samlar forskare, kliniker, branschfolk och andra experter inom omr\u00e5det. <\/span><\/p>\n

 <\/span><\/p>\n

”<\/span>Vi ser fram emot att presentera STA363 och dess potential med ledande internationella sm\u00e4rtforskare. En konferens som SOPATE2022 utg\u00f6r ett viktigt forum f\u00f6r exponering av STA363 mot experter inom klinisk sm\u00e4rtforskning och ett tillf\u00e4lle att bredda v\u00e5rt kontaktn\u00e4t f\u00f6r kliniska studier<\/em><\/span>,\u201d s\u00e4ger Anders Lehmann, CSO i Stayble<\/span><\/p>\n

 <\/span><\/p>\n

Ta del av mer information om SPOATE2022 via l\u00e4nken: <\/span>https:\/\/sopate2022.com\/<\/u><\/span><\/a> <\/span><\/p>\n

 <\/span><\/p>\n

Posterpresentationen finns bifogad i det h\u00e4r pressmeddelandet. <\/span><\/p>\n

 <\/span><\/p>\n

F\u00f6r mer information<\/span><\/h2>\n

Andreas Gerward, VD Stayble Therapeutics AB<\/span><\/p>\n

E-post: andreas.gerward@stayble.se <\/span><\/p>\n

Telefon: +46 730 808<\/span> <\/span>397<\/span><\/p>\n

 <\/span><\/p>\n

Om Stayble Therapeutics AB<\/span><\/h2>\n

Stayble \u00e4r ett kliniskt l\u00e4kemedelsbolag som utvecklar injektionsbehandlingen STA363 mot kronisk diskrelaterad ryggsm\u00e4rta. Behandlingen riktar sig till patienter som inte blir hj\u00e4lpta av sjukgymnastik och sm\u00e4rtstillande preparat. Injektionen ges vid ett tillf\u00e4lle och effekten ber\u00e4knas kvarst\u00e5 hela livet och kr\u00e4va minimal rehabilitering. Bolaget har nu fokus p\u00e5 den fortsatta kliniska utvecklingen och genomf\u00f6r just nu en klinisk fas 2b-studie. Staybles vision \u00e4r att utveckla STA363 som ny standardbehandling f\u00f6r patienter som lider av kronisk diskrelaterad ryggsm\u00e4rta. <\/span><\/p>\n

 <\/span><\/p>\n

Bolagets Certified Adviser \u00e4r Svensk Kapitalmarknadsgranskning AB som n\u00e5s p\u00e5 telefonnummer +46 11 32 30 732 eller e-post <\/span>ca@skmg.se<\/u><\/span><\/a> <\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Stayble Therapeutics AB (\u201dStayble\u201d eller \u201dBolaget\u201d) meddelar att Bolagets p\u00e5g\u00e5ende fas 2b-studien har accepterats f\u00f6r posterpresentation vid 4th European Congress on Clinical Trials in Pain (SOPATE2022). Kongressen h\u00e5lls i Wien, \u00d6sterrike, den 7-8 december 2022.<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5621"}],"collection":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed"}],"about":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/cision-feed"}],"replies":[{"embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/comments?post=5621"}],"version-history":[{"count":0,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5621\/revisions"}],"wp:attachment":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=5621"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}